60 results about "Conjunctivitides" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

The invention relates to compound herba houttuyniae eye drops as well as a preparation method and application of the compound herba houttuyniae eye drops. Comprising the following preparation raw materials in percentage by mass: 1-6% of a herba houttuyniae extracting solution, 1-5% of an aglaia odorata extracting solution, 1-2% of a gelidium amansii extracting solution, 0.1-0.3% of acyclovir, 0.1-0.3% of tobramycin, 0.01-0.1% of dexamethasone sodium phosphate, 0.1-1% of sodium hyaluronate, 0.1-3% of glycerol and 88-93% of purified water. According to the compound herba houttuyniae eye drops prepared by the preparation method disclosed by the invention, the herba houttuyniae extracting solution, the aglaia odorata extracting solution, the gelidium amansii extracting solution, the acyclovir, the tobramycin and the dexamethasone sodium phosphate are combined for use, so that the compound herba houttuyniae eye drops have a relatively good curative effect on pets suffering from bacterium and virus mixed infection type conjunctivitis / keratitis; the compound herba houttuyniae eye drops are good in high-temperature-resistant storage stability and good in curative effect, the problem of frequent administration can be reduced, and the compound herba houttuyniae eye drops are more convenient to use and store.

The present invention relates to a single dose plastic container comprising between 0.2 and 3.0 ml of an aqueous pharmaceutical composition comprising from 0.50 to 1.20 % by weight of povidone-iodine and to its use in the treatment of conjunctivitis.

The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative. The present invention relates to an ophthalmic composition in the form of an aqueous solution containing levofloxacin or salt or derivative thereof and ketorolac or salt or derivative thereof, for use in a method for the treatment of conjunctivitis and for the prevention or treatment of inflammation or prevention of infection after cataract surgery in a subject, according to a dosage regimen that improves patient compliance and tolerability and enables the prevention and treatment of intermediate / antibiotic-resistant infections.

The present invention provides a novel multi-strain probiotic formulation and relates to the use of the multi-strain formulation in therapy, in particular for the treatment or prevention of immunological or allergic diseases / disorders, such as allergic rhinitis or allergic conjunctivitis. In addition, the present invention also provides a novel therapeutic regimen that is easy to follow using the probiotic formulations provided herein.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The invention discloses a preparation method of a non-Newtonian fluid-based temperature-shear dual response type ophthalmic sustained-release drug carrier, and belongs to the technical field of ophthalmic medicines. The preparation is composed of a dispersed phase (a temperature response type targeting nano-drug carrier) and a continuous phase (a non-Newtonian fluid matrix), wherein the mass fraction of the dispersed phase in the continuous phase is 0.5-2%. The temperature response type targeted nano-drug carrier is of a core-shell two-layer structure, the core is composed of a PLGA-PEG copolymer and an active drug, the shell is formed by grafting poly N-isopropylacrylamide (PNIPAM) and hyaluronic acid, and the lowest critical solution temperature (LCST) of the PNIPAM is 35-37 DEG C; the non-Newtonian fluid matrix is a pseudoplastic fluid, is composed of Carbomer 940 and triethanolamine, and has a shear thinning characteristic. The preparation method comprises the following three steps: preparation of the temperature response type targeting nano-drug carrier, preparation of the non-Newtonian fluid matrix and low-speed dispersion and compounding of the two. According to the invention, shear-response convenient administration, temperature-response precise drug release and long-acting retention synergism are realized, the bioavailability of the drug and the compliance of a patient are remarkably improved, the stability is excellent, the preparation process is simple and controllable, and the preparation method is suitable for long-acting targeted therapy of chronic eye diseases such as allergic conjunctivitis, chronic xerophthalmia, glaucoma and the like.

The invention belongs to the technical field of eye care, and provides vitamin B12-containing contact lens lubricating eye drops and a preparation method thereof, and the vitamin B12-containing contact lens lubricating eye drops comprise 0.5 to 0.7 part of sodium hyaluronate, 0.18 to 0.23 part of a tackifier, 0.3 to 0.35 part of polyvinyl alcohol, 1.1 to 1.2 parts of soybean phospholipid, 0.2 to 0.3 part of sodium cromoglycate, 0.7 to 0.9 part of vitamin B12, 0.005 to 0.01 part of borneol, 0.1 to 0.15 part of a surfactant, 0.1 to 0.18 part of a sodium chloride solution, 0.3 to 0.4 part of tiloxamer and 80 to 90 parts of water. The sodium hyaluronate and the polyvinyl alcohol have moisturizing and thickening effects, the sodium cromoglycate can effectively diminish inflammation and kill viruses, and conjunctivitis and other eye diseases are avoided; vitamin B12 can moisten corneas and relieve eye fatigue. Through cooperative use of the raw materials, the effects of moistening eyes, diminishing inflammation and relieving are achieved.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition, a preparation method thereof and application of the traditional Chinese medicine composition in preparation of medicines for treating ophthalmic diseases. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials: flos chrysanthemi, concha haliotidis, semen cassiae torae, honey-fried licorice root and a component A, wherein the component A is selected from at least one of herba schizonepetae, radix puerariae and herba menthae. The composition has the effects of removing heat from the liver and purging heat, and treating red and astringent eye pain, and experiments show that the composition can improve the tear secretion amount, prolong the tear film rupture time and / or protect the corneal epithelium. The traditional Chinese medicine composition can be clinically used for treating dry eyes, asthenopia, keratoconjunctivitis, cataract and vitreous opacity.

The invention belongs to the technical field of medicines, and particularly relates to compound tylosin ophthalmic gel as well as a preparation method and application thereof. The invention relates to compound tylosin ophthalmic gel. The compound tylosin ophthalmic gel is prepared from tylosin tartrate, ganciclovir, pharmaceutic adjuvants and water, the pharmaceutic adjuvants comprise a thickening agent, a filling agent, a solubilizer, a bacteriostatic agent and a pH regulator. The compound tylosin ophthalmic gel disclosed by the invention takes effect quickly, has a remarkable treatment effect on feline conjunctivitis, has a lasting curative effect, and can still keep a relatively good drug effect after drug withdrawal.

The present application provides a rapid detection system for allergic conjunctivitis and its application. Specifically, the present application provides a rapid detection system for detecting allergic conjunctivitis, which comprises: (A) a subject user terminal; and (B) a background processing end. The rapid detection system of the present application can timely, efficiently and accurately evaluate the incidence and severity of allergic conjunctivitis based on the detection results of the levels of IgE and histamine in tears, realize the home detection of allergic conjunctivitis, reduce misdiagnosis and avoid the aggravation of allergic conjunctivitis due to medical delay, which is helpful to improve the medical efficiency and has a broad clinical application prospect.

1. Name of the product in this design: Eye Surface Sample Sampling Bottle. 2. Purpose of this design: A tool for detecting pathogenic microorganisms in conjunctivitis secretions. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. Part A is marked as being made of transparent material.

The present invention provides a composition for alleviating or preventing a symptom of allergic rhinitis or allergic conjunctivitis, the composition containing dihomo-γ-linolenic acid (DGLA) as an active ingredient.

The present invention relates to a nasal pharmaceutical composition comprising alcaftadine or a pharmaceutically acceptable salt and optionally one or more pharmaceutically acceptable excipients, methods of treating allergic rhinitis, allergic rhino-conjunctivitis, or symptoms thereof (such as nasal congestion) with the nasal pharmaceutical composition, and methods of preparing it.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders.

The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl urea derivatives, and further found that the compounds have an antagonistic activity against bradykinin B1 receptor, so that the compounds can be used as novel bradykinin B1 receptor antagonists and can be further used for treating or preventing related diseases caused by abnormal expression of the bradykinin B1 receptor. In particular, the present invention has recently found that N-tetrazolyl aryl urea derivatives have prevention or treatment effects on corona virus disease 2019, pulmonary edema, diabetes complications, allergic conjunctivitis, etc.

The invention provides a composition containing AR-15512, a preparation method of the composition and application of the composition in eye diseases such as xerophthalmia, meibomian gland dysfunction, allergic conjunctivitis and eye pain.

The present invention relates to iota-carrageenan for use as a main or sole active ingredient in an aqueous pharmaceutical composition for the prevention or treatment of non-viral non-allergic clinically relevant eye conditions affecting at least one of mucosal tissues at or around an individual's eye, an eye surface, corneal tissue, and fluid inside the eye, said clinically relevant eye conditions selected from the group consisting of increased intraocular pressure, non- allergic and non-viral conjunctivitis, irritations caused by airborne particulate matter other than allergens, and late complications of non-viral and non-allergic conjunctivitis selected from the group consisting of corneal opacities, subepithelial infiltrates, and formation of ocular pseudomembranes.

The present disclosure relates to heterogeneous cell compositions derived from canine or feline uterine tissue and methods of producing and use thereof. In some aspects, the heterogeneous cell compositions comprise a mixture of mesenchymal progenitor cells and epithelial progenitor cells. In some aspects, the heterogeneous cell compositions are used as an autologous or allogeneic treatment for the treatment of diseases such as chronic kidney disease, atopic dermatitis, immune mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune mediated polyarthritis or wounds in canines and felines.

The invention relates to the technical field of gene engineering, in particular to a primer group for detecting a main pathogen CVA24v of acute hemorrhagic conjunctivitis based on a VP1 region and application of the primer group. The invention provides a primer group for detecting a main pathogen CVA24v of acute hemorrhagic conjunctivitis. The primer group comprises a primer pair and a probe, the nucleotide sequences of the primer pair are as shown in SEQ ID NO.1 and SEQ ID NO.3; the nucleotide sequence of the probe is as shown in SEQ ID NO. 2. The method has reliable repeatability and consistency in practical application, and is suitable for rapid and accurate identification of the main pathogen CVA24v of acute hemorrhagic conjunctivitis in clinical samples and large-scale epidemiological monitoring.

Feline herpesvirus (FHV-1) is a highly contagious virus affecting domestic and wild felines and is the leading cause of corneal disease and conjunctivitis in cats. Thus, provided herein is topical ophthalmic formulation for treating FHV-1, comprising L-lysine and a second therapeutic agent, such as osha root (e.g., ligustilide). The formulation enables direct and concentrated delivery to the ocular surface, which is believed to enhance efficacy in treating herpesvirus infections. This innovative approach improves treatment outcomes by targeting the virus more effectively at the site of infection.

The present disclosure provides use of a polypeptide for the prevention or treatment of allergic conjunctivitis. Also provided is a method for treating or preventing allergic conjunctivitis in a subject in need thereof, comprising administering to the subject an effective amount of any one of the polypeptides disclosed herein.

The invention belongs to the technical field of biological medicine, and particularly relates to a soluble microneedle patch for in-situ drug delivery of trabecular meshwork tissue and a preparation method and application of the soluble microneedle patch. The soluble microneedle patch comprises a fan-ring-shaped backing and a microneedle array arranged on the fan-ring-shaped backing; the micro-needle and the fan-ring-shaped backing are both prepared from polyvinyl alcohol (PVA), the PVA concentration for preparing the micro-needle and the fan-ring-shaped backing is 5%-25%, and the PVA concentration is obtained by weighing 0.5 g-2. 5 g of PVA powder and dissolving the PVA powder in 10 mL of pure water or PBS. The microneedle patch is suitable for delivery of various types of drugs, is expected to be used for treatment of various eye diseases including glaucoma, ocular hypertension, cataract, uveitis, conjunctivitis, xerophthalmia and the like, and has important clinical application value and commercial value.

The application provides a feline calicivirus LZ-2016 strain and a vaccine composition. The feline calicivirus LZ-2016 strain has a high virus titer, the strain has strong pathogenicity to cats, and can cause typical symptoms such as oral ulcer and conjunctivitis. The inactivated product of the strain can produce a good immune response when cats are immunized, has good immunogenicity, can better stimulate the body to produce high-level neutralizing antibodies against FCV, can provide high immunoprotection rate to FCV attack, and has basic potential for developing a vaccine. The strain can be prepared into a vaccine and used for feline calicivirus prevention and treatment, provides an important vaccine virus source for feline calicivirus prevention and control in China, and realizes effective feline calicivirus prevention and control.

The invention relates to the field of medical preparations, and discloses a compound preparation composition containing olopatadine and brimonidine for eyes and a preparation method of the compound preparation composition. The compound preparation composition comprises the following components in percentage by weight: 0.01 to 1.5 percent of olopatadine and 0.01 to 0.8 percent of brimonidine. The compound preparation composition can be used for treating allergic conjunctivitis, glaucoma and ocular surface inflammation at the same time, is especially suitable for patients with coexistence of multiple diseases, and achieves multiple pharmacological effects through one-time administration. Through compound compatibility, the single dosage is reduced, and irritation or systemic side effects are reduced.

The invention discloses a steam eye patch and a preparation method thereof, the steam eye patch comprises an eye patch and a traditional Chinese medicine matrix liquid, the traditional Chinese medicine matrix liquid comprises the following components in parts by mass: 20-50 parts of wild chrysanthemum, 20-50 parts of golden cypress, 10-50 parts of coptis chinensis, 1-5 parts of salvia miltiorrhiza, 1-5 parts of ginseng, 1-5 parts of dendrobe, 0.00001-1 part of natural borneol, 0.00001-1 part of menthol and 0.5-2 parts of xanthan gum. The eye pad prepared by the invention combines the dual effects of physical hot compress and traditional Chinese medicine components, and various experiments prove that the eye pad can relieve meibomian gland atrophy and blockage, relieve conjunctivitis, keratitis and other inflammatory reactions, improve tear secretion and reduce xerophthalmia, and is very suitable for eye care.

The invention relates to the technical field of medicines, and finds that a natural product amentoflavone can be used as a GPR35 (G-protein coupled receptor 35, GPR35) receptor agonist and application thereof, the compound is amentoflavone, has GPR35 receptor agonist activity, is a GPR35 receptor agonist, can be used for treating thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction, and can be used for treating various diseases such as thromboembolic diseases, spring conjunctivitis, intracranial embolism, primary sclerosing cholangitis and myocardial infarction. Therefore, a novel GPR35 receptor stimulant seedling compound with a clear action target can be provided for the related diseases.

The present invention discloses a novel chalcone compound, a preparation method, a pharmaceutical composition, and applications thereof, belonging to the field of pharmaceutical technology. The chalcone compound (±)-Lupulusone A provided by the present invention has not been reported to date. Experimental results show that the chalcone compound provided by the present invention has significant anti-inflammatory activity against lipopolysaccharide-induced RAW 264.7 cells, significantly superior to the positive drug dexamethasone. It can be used to develop drugs for treating various inflammatory-related diseases, including but not limited to pneumonia, hepatitis, nephritis, arthritis, conjunctivitis, gastroenteritis, metabolic syndrome, diabetes, cancer, etc.

The invention belongs to the technical field of chemical synthesis of medicines, and particularly relates to a preparation process of azelastine hydrochloride, which comprises four steps of condensation reduction, hydrochloric acid hydrolysis, cyclization and hydrochloric acid salification. According to the method, the reaction efficiency, the product yield and the purity are improved, the production cost and the operation difficulty are reduced, and a stable, cost-controllable and repeatable preparation process is formed. The prepared azelastine hydrochloride is a long-acting anti-allergic drug, has dual effects of resisting histamine and inflammation, has high affinity to a receptor, effectively blocks histamine release of mast cells and basic granulocytes, has wide pharmacological effects on leukotriene, kinin, platelet activating factors and other inflammatory chemical mediators, and can be used for preparing an anti-allergic drug. Therefore, azelastine can effectively relieve typical symptoms of allergic conjunctivitis, such as pruritus, conjunctival congestion, lacrimation, conjunctival edema and the like.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.